Rapamycin formulations for oral administration

Details Rapamycin formulations for oral administration Rapamycin formulations for oral administration

1994-09-09

1996-07-16

Spivack, Phyllis G.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

A61K 31445

Patent

active

055367291

ABSTRACT:
The present invention provides novel oral rapamycin formulations which have, per 100 ml of the formulation, from about 0.01 grams to about 5.0 grams of rapamycin, from about 0.05% to about 10% by volume of surfactant, and from about 75% to about 99.95% by volume of a solution of phospholipid or lecithin in which the phospholipid or lecithin therein is 40% to 75% by weight.

REFERENCES:
patent: 3929992 (1975-12-01), Sehgal et al.
patent: 3993749 (1976-11-01), Sehgal et al.
patent: 4885171 (1989-12-01), Surendra et al.
patent: 5080899 (1992-01-01), Sturm et al.
patent: 5100899 (1992-03-01), Caln
Physicians' Desk Reference, 45th ed., 1991, pp. 2119-2122, Medical Economics Company, Inc.
Physicians' Desk Reference, 45th ed., 1991, pp. 785-787, Medical Economics Company, Inc.
Luke et al., Effects of Cyclosporine on the Isolated Perfused Rat Kidney, Transplantation, vol. 43, No. 6, pp. 795-799, 1987.
Venkataram, et al., Pharmacokinetics of Two Alternative Dosage Forms for Cyclosporine: Liposomes and Intralipid, Journal of Pharmaceutical Sciences, vol. 79, No. 3, pp. 216-219, 1990.
Thiel, et al., Acutely Impaired Renal Function During Intravenous Administration of Cyclosporine A: A Cremaphore Side-Effect, Clinical Nephrology, vol. 25, Suppl. No. 1, pp. S40-S42, 1986.
Honbo, et al., The Oral Dosage Form of FK-506, Transplantation Proceedings, vol. XIX, No. 5, Suppl. 6, pp. 17-22, 1987.
Stepkowski, et al., Rapamycin, A Potent Immunosuppressive Drug for Vascularized Heart, Kidney, and Small Bowel Transplantation in the Rat, Transplantation, vol. 51, No. 1, pp. 22-24, 1991.
Kahan, et al., Synergistic Interactions of Cyclosporine and Rapamycin to Inhibit Immune Performances of Normal Human Peripheral Blood Lymphocytes In Vitro, Transplantation, vol. 51, No. 1, pp. 232-237, 1991.
Intl. Pharm. Abstracts--FK--506, Immunosuppressant for the 1990s, Macleod, et al., Lancet, 337, pp. 25-27, Jan. 5, 1991.
Intl. Pharm. Abstracts, FK-506: Discussion of a New Investigationsl Drug, C. G. Forde, ASHP Midyear Clinical Meeting, 25, p. 446D, Dec. 1990.
Intl. Pharm. Abstracts, FK-506, Kidney Transplantation Under FK 506, Starzl, et al., JAMA, 264, pp. 63-67, Jul. 4, 1990.
Intl. Pharm. Abstrcts-FK-506 In Steroid--Resistant Focal Sclerosing Glomerulonephritis of Childhood, McCauley, et al., Lancet, 335, p. 674, Mar. 17, 1990.
Intl. Pharm. Abstracts, New Drug Could Replace Cyclosporin in Transplant Drug Therapy, Anon, Am. Pharm. NS, 30, 16, Jan. 1990.
Intl. Pharm. Abstracts, Treatment of Cyclosporin Induced Hemolytic-Uremic Syndrome with FK-506, McCauley, et al., Lancet, 2, 1516, Dec. 23-30, 1989.
Intl. Pharm. Abstracts-FK-506 for Liver, Kidney, and Pancreas Transplantation; Starzl, et al., Lancet, 2, 1000-1004, Oct. 28, 1989.

Affiliated with

Also associated with

Rating

Rapamycin formulations for oral administration does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Rapamycin formulations for oral administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rapamycin formulations for oral administration will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1784536